ranolazine has been researched along with Chronic Disease in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (60.66) | 29.6817 |
| 2010's | 24 (39.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, Z; Teng, S; Zhao, K | 1 |
| Alexander, KP; Barefoot, J; Ben-Yehuda, O; Brucker, A; Davidson-Ray, L; Fanaroff, AC; Mark, DB; Ohman, EM; Prather, K; Stone, GW; Weisz, G; Williams, RB; Wojdyla, D | 1 |
| Gosch, K; Grantham, JA; Karmpaliotis, D; Kirtane, A; Lombardi, W; Moses, J; Nicholson, W; Peri-Okonny, PA; Salisbury, AC; Sapontis, J; Spertus, JA | 1 |
| Arnold, SV; Cohen, DJ; Grantham, JA; Hirai, T; Jones, P; Karmpaliotis, D; Lombardi, W; Moses, J; Nicholson, WJ; Patterson, C; Qintar, M; Salisbury, AC; Sapontis, J; Sheehy, J; Spertus, JA; Tang, Y | 1 |
| Rumsfeld, JS | 1 |
| Trujillo, TC | 1 |
| Grehan, S; Muhlestein, JB | 1 |
| Hidalgo-Vega, A; Ramos-Goñi, JM; Villoro, R | 1 |
| Banon, D; Budlovsky, T; Eisenberg, MJ; Filion, KB; Franck, C | 1 |
| Coleman, CI; Kohn, CG; Limone, BL; Parker, MW | 2 |
| Acharjee, S; Codolosa, JN; Figueredo, VM | 1 |
| Arnold, SV; Belardinelli, L; Ben-Yehuda, O; Chaitman, BR; Jones, PG; Kosiborod, M; Li, Y; McGuire, DK; Olmsted, A; Spertus, JA; Yue, P | 1 |
| Ghushchyan, V; Hartsfield, CL; Koch, BR; Nair, KV; Page, RL; Read, RA | 1 |
| Arnold, SV; Belardinelli, L; Chaitman, BR; Inzucchi, SE; Kosiborod, M; McGuire, DK; Spertus, JA; Tang, F; Yue, P | 1 |
| Coleman, CI; Freemantle, N; Kohn, CG | 1 |
| Gourzoulidis, G; Kanakakis, J; Kourlaba, G; Maniadakis, N; Parissis, J; Vlachopoulos, C | 1 |
| Rayner-Hartley, E; Sedlak, T | 1 |
| Allard, M; Ben-Yehuda, O; Berg, J; Gottwald, M; Jochelson, P; Juan, A; Pannacciulli, N; Shao, Y; Zack, J; Zhang, H | 1 |
| Banerjee, A; Banerjee, K; Ghosh, RK; Gupta, A; Kamatam, S | 1 |
| Conti, CR | 2 |
| Boden, WE; Eid, F | 1 |
| Arora, R; Jawad, E | 1 |
| Nash, DT; Nash, SD | 1 |
| Keating, GM | 1 |
| Arora, RR; Patel, PD | 1 |
| Braunwald, E; Buros, JL; Chaitman, BR; Karwatowska-Prokopczuk, E; Morrow, DA; Murphy, SA; Scirica, BM; Wilson, SR | 1 |
| Milne, HC; Vallerand, AH | 1 |
| Kloner, RA; Reffelmann, T | 1 |
| Aslam, S; Gray, D | 1 |
| Reddy, BM; Schwartzbard, AZ; Weintraub, HS | 1 |
| Franck, AJ; Frohnapple, DJ; Gillette, MA; Reeder, DN | 1 |
| Ben-Yehuda, O; Cheng, ML; Lee, S; Sendón, JL | 1 |
| Di Monaco, A; Sestito, A | 1 |
| Blackburn, B; Chandler, MP; Morita, H; Roth, BA; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A | 1 |
| Chaitman, BR | 3 |
| Biesiadecki, BJ; Blackburn, B; Chandler, MP; Chaudhry, P; Mishima, T; Nass, O; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A | 1 |
| Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA | 1 |
| Busti, AJ; Hooper, JS | 1 |
| Pechlaner, C; Wiedermann, C | 1 |
| Gratsianskiĭ, NA | 1 |
| Cocco, G; Pouleur, H; Rousseau, MF; Wolff, AA | 1 |
| Chaitman, BR; Crager, M; Timmis, AD | 1 |
| McCullough, PA | 1 |
| Aguiar-Souto, P; Ortigosa-Aso, FJ; Silva-Melchor, L | 1 |
| Arora, R; Parang, P; Singh, B | 1 |
| Barsness, GW; Yang, EH | 1 |
| Gaffney, SM | 1 |
| Keam, SJ; Siddiqui, MA | 2 |
| Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH | 1 |
| Crager, MR; Koren, MJ; Sweeney, M | 1 |
| Dobesh, PP; Trujillo, TC | 1 |
| Chaitman, BR; Sano, J | 1 |
| Stanley, WC | 1 |
24 review(s) available for ranolazine and Chronic Disease
| Article | Year |
|---|---|
The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
Topics: Acetanilides; Angina, Stable; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome | 2014 |
Update on ranolazine in the management of angina.
Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Cost Savings; Cost-Benefit Analysis; Drug Costs; Hospital Costs; Hospitalization; Humans; Piperazines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
Ranolazine: A Contemporary Review.
Topics: Angina, Stable; Animals; Cardiovascular Agents; Chronic Disease; Drug Interactions; Drug Labeling; Humans; Off-Label Use; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2016 |
Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
Topics: Aged; Angina Pectoris; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Ranolazine; Risk Assessment; Role; Sodium Channel Blockers; Survival Analysis; Treatment Outcome | 2017 |
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agents; Benzazepines; Bosentan; Chronic Disease; Counterpulsation; Cyclic Nucleotide-Gated Cation Channels; Exercise Test; Heart Murmurs; Humans; Ivabradine; Myocardial Contraction; Myocardial Ischemia; Myocardial Revascularization; Myocardium; Nicorandil; Oxygen Consumption; Perhexiline; Piperazines; Protein Kinase Inhibitors; Ranolazine; Sulfonamides; Trimetazidine; Vasodilator Agents | 2008 |
Ranolazine for chronic stable angina.
Topics: Acetanilides; Aged; Aged, 80 and over; Angina Pectoris; Chronic Disease; Dosage Forms; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Piperazines; Ranolazine; Sex Factors | 2008 |
Ranolazine: a review of its use in chronic stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Ranolazine | 2008 |
Utility of ranolazine in chronic stable angina patients.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Diabetes Complications; Glycated Hemoglobin; Humans; Piperazines; Ranolazine; Treatment Outcome | 2008 |
Chronic angina and the treatment with ranolazine: facts and recommendations.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2009 |
Ranolazine: an anti-anginal drug with further therapeutic potential.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Nitroglycerin; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Survival Rate; Treatment Outcome; United States | 2010 |
Ranolazine (Ranexa) in the treatment of chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2010 |
Ranolazine: a new approach to treating an old problem.
Topics: Acetanilides; Angina Pectoris; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Evidence-Based Medicine; Heart Diseases; Heart Failure, Diastolic; Humans; Myocardial Infarction; Piperazines; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2010 |
The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina, Stable; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chronic Disease; Coronary Artery Bypass; Disease Management; Heart Function Tests; Humans; Membrane Transport Modulators; Myocardial Ischemia; Nitrates; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Ranolazine | 2012 |
Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Chronic Disease; Enzyme Inhibitors; Exercise; Exercise Test; Hemodynamics; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Risk Factors; Treatment Outcome; United States | 2002 |
Chronic angina: new medical options for treatment.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2005 |
Metabolic modulators for chronic cardiac ischemia.
Topics: Acetanilides; Animals; Carnitine; Chronic Disease; Drug Evaluation, Preclinical; Enzyme Inhibitors; Heart; Humans; Lipid Metabolism; Myocardial Ischemia; Myocardium; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Trimetazidine; Vasodilator Agents; Vitamin B Complex | 2005 |
Evolving treatment strategies for chronic refractory angina.
Topics: Acetanilides; Angina Pectoris; Arginine; Benzazepines; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Counterpulsation; Electric Stimulation Therapy; Humans; Ivabradine; Myocardial Revascularization; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Spinal Cord | 2006 |
Ranolazine, a novel agent for chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Enzyme Inhibitors; Guidelines as Topic; Humans; Piperazines; Ranolazine | 2006 |
Ranolazine: a review of its use in chronic stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2006 |
Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.
Topics: Acetanilides; Administration, Oral; Angina Pectoris; Biological Availability; Cardiovascular Diseases; Chronic Disease; Delayed-Action Preparations; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2006 |
Spotlight on ranolazine in chronic stable angina pectoris.
Topics: Acetanilides; Administration, Oral; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Ranolazine: a new option in the management of chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Drug Interactions; Enzyme Inhibitors; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2007 |
Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Chronic Disease; Enzyme Inhibitors; Humans; Ivabradine; Myocardial Ischemia; Nicorandil; Nitro Compounds; Piperazines; Ranolazine; rho-Associated Kinases; Sinoatrial Node; Trimetazidine; Vasodilator Agents | 2007 |
Partial fatty acid oxidation inhibitors for stable angina.
Topics: Acetanilides; Adenosine Triphosphate; Angina Pectoris; Chronic Disease; Energy Metabolism; Fatty Acids; Humans; Myocardium; Oxidation-Reduction; Oxygen Consumption; Piperazines; Ranolazine; Trimetazidine | 2002 |
14 trial(s) available for ranolazine and Chronic Disease
| Article | Year |
|---|---|
Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris.
Topics: Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Health Status; Humans; Male; Middle Aged; Morbidity; Myocardial Revascularization; Prognosis; Quality of Life; Ranolazine; Sodium Channel Blockers; United States | 2019 |
Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Male; Markov Chains; Middle Aged; Piperazines; Placebos; Ranolazine; Spain | 2014 |
Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Topics: Acetanilides; Angina, Stable; Chronic Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Costs; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Piperazines; Quality-Adjusted Life Years; Ranolazine; Standard of Care; United States | 2014 |
Impact of angina frequency on health utility values of patients with chronic stable angina.
Topics: Acetanilides; Angina, Stable; Chronic Disease; Double-Blind Method; Enzyme Inhibitors; Female; Health Status Indicators; Humans; Male; Middle Aged; Piperazines; Placebos; Quality of Life; Ranolazine; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2014 |
Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
Topics: Acetanilides; Angina, Stable; Chronic Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Male; Middle Aged; Piperazines; Ranolazine; Retrospective Studies; Treatment Outcome | 2014 |
Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
Topics: Aged; Angina, Stable; Blood Glucose; Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Ranolazine; Retrospective Studies | 2015 |
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Angina Pectoris; Animals; Area Under Curve; Cardiovascular Agents; CHO Cells; Chronic Disease; Comorbidity; Cricetulus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Organic Cation Transporter 2; Polypharmacy; Ranolazine; United States | 2015 |
Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Angina Pectoris; Chronic Disease; Cohort Studies; Confidence Intervals; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Exercise Tolerance; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Piperazines; Proportional Hazards Models; Ranolazine | 2009 |
Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Topics: Acetanilides; Angina, Stable; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Enzyme Inhibitors; Exercise Test; Exercise Tolerance; Follow-Up Studies; Humans; Incidence; Piperazines; Prospective Studies; Ranolazine; Spain; Treatment Outcome | 2012 |
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Amlodipine; Angina Pectoris; Atenolol; Calcium Channel Blockers; Cardiovascular Agents; Chronic Disease; Diltiazem; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Nitroglycerin; Physical Exertion; Piperazines; Ranolazine; Survival Analysis | 2004 |
Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Topics: Acetanilides; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Female; Heart Rate; Humans; Linear Models; Male; Middle Aged; Myocardial Ischemia; Piperazines; Ranolazine; Treatment Outcome | 2005 |
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
Topics: Acetanilides; Aged; Angina Pectoris; Chronic Disease; Diabetic Angiopathies; Double-Blind Method; Enzyme Inhibitors; Exercise Tolerance; Female; Glycated Hemoglobin; Humans; Male; Nitroglycerin; Piperazines; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Nitroglycerin; Piperazines; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Topics: Acetanilides; Administration, Oral; Adult; Aged; Angina Pectoris; Chronic Disease; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Enzyme Inhibitors; Exercise Test; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Piperazines; Probability; Proportional Hazards Models; Ranolazine; Risk Assessment; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2007 |
23 other study(ies) available for ranolazine and Chronic Disease
| Article | Year |
|---|---|
Vagal Stimulation Facilitates Improving Effects of Ranolazine on Cardiac Function in Rats with Chronic Ischemic Heart Failure.
Topics: Animals; Chronic Disease; Cytokines; Disease Models, Animal; Heart Failure; Male; Myocardial Ischemia; Nerve Tissue Proteins; Norepinephrine; Ranolazine; Rats; Rats, Sprague-Dawley; Vagus Nerve Stimulation; Ventricular Function, Left | 2018 |
Physical Activity After Percutaneous Coronary Intervention for Chronic Total Occlusion and Its Association With Health Status.
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Coronary Occlusion; Exercise; Exercise Tolerance; Female; Follow-Up Studies; Health Status; Humans; Male; Middle Aged; Nitrates; Percutaneous Coronary Intervention; Ranolazine; Treatment Outcome | 2019 |
De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Chi-Square Distribution; Chronic Disease; Coronary Occlusion; Dyspnea; Female; Health Status; Health Surveys; Humans; Logistic Models; Male; Myocardial Ischemia; Nitro Compounds; Percutaneous Coronary Intervention; Prospective Studies; Quality of Life; Ranolazine; Registries; Time Factors | 2019 |
Introduction: Managing patients with chronic angina: emerging therapeutic options for improving clinical efficacy and outcomes.
Topics: Acetanilides; Angina, Stable; Cardiovascular Agents; Chronic Disease; Health Care Costs; Humans; Piperazines; Ranolazine | 2006 |
Advances in the management of stable angina.
Topics: Acetanilides; Angina, Stable; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chronic Disease; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Humans; Long QT Syndrome; Piperazines; Ranolazine | 2006 |
Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Angina, Stable; Chronic Disease; Female; Humans; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Quality of Life; Ranolazine; Severity of Illness Index; Sodium Channel Blockers; Surveys and Questionnaires; Treatment Outcome | 2013 |
Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; Chronic Disease; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Health Resources; Humans; Male; Nitroglycerin; Ranolazine; Retrospective Studies; Risk Factors; Treatment Outcome; United States; Vasodilator Agents | 2015 |
Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Topics: Aged; Angina, Stable; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Female; Humans; Male; Quality of Life; Quality-Adjusted Life Years; Ranolazine; Sodium Channel Blockers; Surveys and Questionnaires; United Kingdom | 2015 |
Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Topics: Angina Pectoris; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Greece; Humans; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Ranolazine; Standard of Care | 2015 |
Expanding the understanding of the treatment of chronic angina: a 21st century approach--part 1.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Chronic Disease; Coronary Artery Bypass; Enzyme Inhibitors; Humans; Incidence; Life Style; Patient Education as Topic; Piperazines; Ranolazine; Treatment Outcome; United States | 2008 |
The evolving role of medical therapy for chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Coronary Artery Bypass; Disease-Free Survival; Enzyme Inhibitors; Humans; Piperazines; Platelet Aggregation Inhibitors; Ranolazine; Risk Factors; Risk Reduction Behavior | 2008 |
Expanding the understanding of the treatment of chronic angina: a 21st century approach-part II.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Chronic Disease; Enzyme Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2008 |
Clinical experience with ranolazine in a veteran population with chronic stable angina.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Stable; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitroglycerin; Piperazines; Ranolazine; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vasodilator Agents; Veterans | 2012 |
Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure.
Topics: Acetanilides; Animals; Cardiotonic Agents; Chronic Disease; Coronary Circulation; Disease Models, Animal; Dobutamine; Dogs; Drug Administration Schedule; Fatty Acids, Nonesterified; Glucose; Heart; Heart Failure; Heart Rate; Lactic Acid; Myocardium; Oxygen Consumption; Piperazines; Ranolazine; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetanilides; Acetyl-CoA C-Acyltransferase; Animals; Carbon-Carbon Double Bond Isomerases; Chronic Disease; Disease Models, Animal; Dogs; Enoyl-CoA Hydratase; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Hemodynamics; Injections, Intravenous; Models, Cardiovascular; Piperazines; Racemases and Epimerases; Radiography; Ranolazine; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2002 |
FDA evaluating new angina drug.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Drug Approval; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; United States; United States Food and Drug Administration | 2004 |
Ranolazine as add-on therapy for patients with severe chronic angina.
Topics: Acetanilides; Angina Pectoris; Antihypertensive Agents; Cardiovascular Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Piperazines; Ranolazine | 2004 |
Ranolazine as add-on therapy for patients with severe chronic angina.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2004 |
Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Topics: Acetanilides; Administration, Oral; Aged; Angina Pectoris; Aryl Hydrocarbon Hydroxylases; Chronic Disease; Clinical Trials as Topic; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Electrocardiography; Energy Metabolism; Exercise Test; Female; Humans; Long QT Syndrome; Male; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Single-Blind Method; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
[Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA].
Topics: Acetanilides; Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Cardiovascular Agents; Chronic Disease; Diltiazem; Double-Blind Method; Exercise Test; Humans; Multicenter Studies as Topic; Piperazines; Placebos; Randomized Controlled Trials as Topic; Ranolazine; Time Factors; Vasodilator Agents | 2004 |
Chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Drug Interactions; Enzyme Inhibitors; Humans; Hypotension; Nitrates; Phosphodiesterase Inhibitors; Piperazines; Ranolazine; Time Factors | 2005 |
Ranolazine (ranexa) for chronic angina.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2006 |
New angina medication approved.
Topics: Acetanilides; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Ranolazine | 2006 |